Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit

American Journal of Gastroenterology

Volumn 111, Issue 11, 2016, Pages 1641-1648

  Faleck, David M ^a   Salmasian, Hojjat ^b   Furuya, E Yoko ^b,c   Larson, Elaine L ^d   Abrams, Julian A ^b,d   Freedberg, Daniel E ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Department of Medicine   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; PROTON PUMP INHIBITOR; SULTAMICILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BACTERIAL GENE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; DEMOGRAPHY; FEMALE; HAZARD RATIO; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TOXIN B GENE; ARTIFICIAL VENTILATION; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; HEMODIALYSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTOCLOSTRIDIUM DIFFICILE; STATISTICS AND NUMERICAL DATA;

AGED; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; COMORBIDITY; CROSS INFECTION; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; RENAL DIALYSIS; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84984799186     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.343     Document Type: Article

References (58)

1. Dubberke ER, Butler AM, Reske KA et al. Attributable outcomes of endemic Clostridium difficile -associated disease in nonsurgical patients. Emerg Infect Dis 2008; 14: 1031.
2. Lagu T, Stefan MS, Haessler S et al. The impact of hospital-onset Clostridium difficile infection on outcomes of hospitalized patients with sepsis. J Hosp Med 2014; 9: 411-7.
3. Ghantoji S, Sail K, Lairson D et al. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010; 74: 309-18.
4. Gabriel L, Beriot-Mathiot A.. Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review. J Hosp Infect 2014; 88: 12-21.
5. Lessa FC, Mu Y, Bamberg WM et al. Burden of C lostridium difficile infection in the United States. N Engl J Med 2015; 372: 825-34.
6. Magill SS, Edwards JR, Bamberg W et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370: 1198-208.
7. Bobo LD, Dubberke ER.. Recognition and prevention of hospital-associated enteric infections in the intensive care unit. Crit Care Med 2010; 38: S324 - S334.
8. Lofgren ET, Cole SR, Weber DJ et al. Hospital-acquired Clostridium difficile infections: estimating all-cause mortality and length of stay. Epidemiology 2014; 25: 570-5.
9. Collins CE, Ayturk MD, Flahive JM et al. Epidemiology and outcomes of community-acquired Clostridium difficile infections in Medicare beneficiaries. J Am Coll Surg 2014; 218: 1141-1147.e1.
10. Deshpande A, Pasupuleti V, Thota P et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013; 68: 1951-61.
11. Furuya-Kanamori L, Stone JC, Clark J et al. Comorbidities, exposure to medications, and the risk of community-acquired Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 2015; 36: 132-41.
12. Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist 2014; 7: 63-72.
13. Soes LM, Holt HM, Bottiger B et al. Risk factors for Clostridium difficile infection in the community: a case-control study in patients in general practice, Denmark, 2009-2011. Epidemiol Infect 2014; 142: 1437-48.
14. Taori SK, Wroe A, Hardie A et al. A prospective study of communityassociated Clostridium difficile infections: the role of antibiotics and co-infections. J Infect 2014; 69: 134-44.
15. Loo VG, Bourgault AM, Poirier L et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365: 1693-703.
16. Barbut F, Corthier G, Charpak Y et al. Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study. Arch Intern Med 1996; 156: 1449-54.
17. Campbell KA, Phillips MS, Stachel A et al. Incidence and risk factors for hospital-acquired Clostridium difficile infection among inpatients in an orthopaedic tertiary care hospital. J Hosp Infect 2013; 83: 146-9.
18. Dial S, Alrasadi K, Manoukian C et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Cmaj 2004; 171: 33-8.
19. Freedberg DE, Salmasian H, Friedman C et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol 2013; 108: 1794-801.
20. Rao K, Micic D, Chenoweth E et al. Poor functional status as a risk factor for severe Clostridium difficile infection in hospitalized older adults. J Am Geriatr Soc 2013; 61: 1738-42.
21. Shivashankar R, Khanna S, Kammer PP et al. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol 2013; 11: 1466-71.
22. Wang X, Cai L, Yu R et al. ICU-onset Clostridium difficile infection in a University Hospital in China: a prospective cohort study. PLoS One 2014; 9: e111735.
23. Ang CW, Heyes G, Morrison P et al. The acquisition and outcome of ICUacquired Clostridium difficile infection in a single centre in the UK. J Infect 2008; 57: 435-40.
24. Micek ST, Schramm G, Morrow L et al. C lostridium difficile infection: a multicenter study of epidemiology and outcomes in mechanically ventilated patients. Crit Care Med 2013; 41: 1968-75.
25. Musa SA, Moran C, Thomson SJ et al. C lostridium difficile -associated disease acquired in the cardiothoracic intensive care unit. J Cardiothorac Vasc Anesth 2011; 25: 263-7.
26. Bobo LD, Dubberke ER, Kollef M. Clostridium difficile in the ICU: the struggle continues. Chest 2011; 140: 1643-53.
27. Surawicz CM, Brandt LJ, Binion DG et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478-98.
28. Balihar K, Kozak F, Kozeluhova J et al. C lostridium difficile infection in hospitalized patients at a Czech tertiary center: analysis of epidemiology, clinical features, and risk factors of fulminant course. Eur J Gastroenterol Hepatol 2014; 26: 880-7.
29. Kwok CS, Arthur AK, Anibueze CI et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107: 1011-9.
30. Janarthanan S, Ditah I, Adler DG et al. Clostridium difficil e-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107: 1001-10.
31. Vincent C, Stephens DA, Loo VG et al. Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection. Microbiome 2013; 1 18.
32. Zaborin A, Smith D, Garfield K et al. Membership and behavior of ultralow- diversity pathogen communities present in the gut of humans during prolonged critical illness. MBio 2014; 5: e01361-14.
33. Ukleja A. Altered GI motility in critically Ill patients: current understanding of pathophysiology, clinical impact, and diagnostic approach. Nutr Clin Pract 2010; 25: 16-25.
34. CDC. Multidrug-Resistant Organism and Clostridium difficile Infection (MDRO/CDI) Module, 2015 (cited 2015 2 Feb). Available at http://www. cdc.gov/nhsn/PDFs/pscManual/12pscMDRO-CDADcurrent.pdf; last accessed on 17 August 2016.
35. Hensgens MP, Goorhuis A, Dekkers OM et al. Time interval of increased risk for Clostridium difficile infection aft er exposure to antibiotics. J Antimicrob Chemother 2012; 67: 742-8.
36. Szeto HC, Coleman RK, Gholami P et al. Accuracy of computerized outpatient diagnoses in a Veterans Affairs general medicine clinic. Am J Manag Care 2002; 8: 37-43
37. Salmasian H, Freedberg DE, Friedman C.. Deriving comorbidities from medical records using natural language processing. J Am Med Inform Assoc 2013; 20: e239 - e242.
38. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
39. Britton RA, Young VB.. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 2014; 146: 1547-53.
40. Lawrence SJ, Puzniak LA, Shadel BN et al. C lostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure. Infect Control Hosp Epidemiol 2007; 28: 123-30.
41. Marra AR, Edmond MB, Wenzel RP et al. Hospital-acquired Clostridium difficile -associated disease in the intensive care unit setting: epidemiology, clinical course and outcome. BMC Infect Dis 2007; 7 42.
42. Kenneally C, Rosini JM, Skrupky LP et al. Analysis of 30-day mortality for Clostridium difficile -associated disease in the ICU setting. Chest 2007; 132: 418-24.
43. Shaughnessy MK, Micielli RL, DePestel DD et al. Evaluation of hospital room assignment and acquisition of Clostridium difficile infection. Infect Control Hosp Epidemiol 2011; 32: 201-6.
44. Dubberke ER, Reske KA, Yan Y et al. Clostridium difficile -associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007; 45: 1543-9.
45. Stein RR, Bucci V, Toussaint NC et al. Ecological modeling from time-series inference: insight into dynamics and stability of intestinal microbiota. PLoS Comput Biol 2013; 9: e1003388.
46. Lewis BB, Buffie CG, Carter R et al. Loss of microbiota-mediated colonization resistance to Clostridium difficile infection is greater following oral vancomycin as compared with metronidazole. J Infect Dis 2015; 212: 1656-65.
47. Seto CT, Jeraldo P, Orenstein R et al. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome 2014; 2 42.
48. Jackson MA, Goodrich JK, Maxan ME et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 2016; 65: 749-56.
49. Imhann F, Bonder MJ, Vich Vila A et al. Proton pump inhibitors affect the gut microbiome. Gut 2016; 65: 740-8.
50. Zhernakova A, Kurilshikov A, Bonder MJ et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 2016; 352: 565-9.
51. Freedberg DE, Toussaint NC, Chen SP et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology 2015; 149: 883-5.e9.
52. Rosen R, Hu L, Amirault J et al. 16S community profiling identifies proton pump inhibitor related differences in gastric, lung, and oropharyngeal microflora. J Pediatr 2015; 166: 917-23.
53. Barletta JF, Sclar DA.. Proton pump inhibitors increase the risk for hospitalacquired Clostridium difficile infection in critically ill patients. Crit Care 2014; 18: 714.
54. Buendgens L, Bruensing J, Matthes M et al. Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile -associated diarrhea. J Crit Care 2014; 29: 696.e11-696.e15.
55. MacLaren R, Reynolds PM, Allen RR.. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med 2014; 174: 564-74.
56. Howell MD, Novack V, Grgurich P et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170: 784-90.
57. Sabatino A, Regolisti G, Brusasco I et al. Alterations of intestinal barrier and microbiota in chronic kidney disease. Nephrol Dial Transplant 2014; 30: 924-33.
58. Christensen S, Johansen MB, Christiansen CF et al. Comparison of Charlson comorbidity index with SAPS and APACHE scores for prediction of mortality following intensive care. Clin Epidemiol 2011; 3: 203-11.